A distinct cutaneous reaction to sorafenib and a multikinase inhibitor.
Joncas
Valérie
V
Sammour
Rita
R
Krasny
Mark
M
Bouffard
Danielle
D
Provost
Nathalie
N
D000284:Administration, Oral; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006257:Head; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009333:Neck; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D017444:Skin Diseases, Papulosquamous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000077157:Sorafenib; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib